A
Andrew P. Brown
Researcher at AstraZeneca
Publications - 14
Citations - 1115
Andrew P. Brown is an academic researcher from AstraZeneca. The author has contributed to research in topics: Osimertinib & Lung cancer. The author has an hindex of 7, co-authored 10 publications receiving 629 citations. Previous affiliations of Andrew P. Brown include Guangdong General Hospital.
Papers
More filters
Journal ArticleDOI
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Thanyanan Reungwetwattana,Kazuhiko Nakagawa,Byoung Chul Cho,Manuel Cobo,Eun Kyung Cho,Alessandro Bertolini,Sabine Bohnet,Caicun Zhou,Ki Hyeong Lee,Naoyuki Nogami,Isamu Okamoto,Natasha B. Leighl,Rachel Hodge,Astrid McKeown,Andrew P. Brown,Yuri Rukazenkov,Suresh S. Ramalingam,Johan Vansteenkiste +17 more
TL;DR: Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer and these results suggest a reduced risk of CNS progression with osimert inib versus standard EGFR -TKIs.
Journal ArticleDOI
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
Yi-Long Wu,Myung-Ju Ahn,Marina Chiara Garassino,Ji Youn Han,Nobuyuki Katakami,Hye Ryun Kim,Rachel Hodge,Paramjit Kaur,Andrew P. Brown,Dana Ghiorghiu,Vassiliki A. Papadimitrakopoulou,Tony Mok +11 more
TL;DR: Osimertinib demonstrated superior CNS efficacy versus platinum-pemetrexed in T790M-positive advanced NSCLC, and was reported the first comparative evidence of osimert inib CNS efficacy compared with platinum- pemetrexe from a phase III study.
Journal ArticleDOI
Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study
James Chih-Hsin Yang,Sang We Kim,Dong Wan Kim,Jong Seok Lee,Byoung Chul Cho,Jin Seok Ahn,Dae H. Lee,Tae Min Kim,Jonathan W. Goldman,Ronald B. Natale,Andrew P. Brown,Barbara Collins,Juliann Chmielecki,Karthick Vishwanathan,Karthick Vishwanathan,Ariadna Mendoza-Naranjo,Myung-Ju Ahn +16 more
TL;DR: Osimertinib showed meaningful therapeutic efficacy in the CNS and a manageable safety profile at 160 mg once daily in patients with EGFRm NSCLC and LM and the adverse event and PK profiles were consistent with previous reports for osimert inib.
Journal ArticleDOI
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Myung-Ju Ahn,Chao-Hua Chiu,Ying Cheng,Ji-Youn Han,Sarah B. Goldberg,Alastair Greystoke,Jeffrey Crawford,Yanqiu Zhao,X. Huang,Martin Johnson,Karthick Vishwanathan,James W.T. Yates,Andrew P. Brown,Ariadna Mendoza-Naranjo,Tony Mok +14 more
TL;DR: Patients with EGFR T790M-positive NSCLC and radiologically detected LM obtained clinical benefit from osimertinib (80 mg qd) and similar non-CNS and LM responses between the patients in AURA LM and BLOOM programs were revealed.
Journal ArticleDOI
A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer.
Andrea Varrone,Katarina Varnäs,Aurelija Jucaite,Aurelija Jucaite,Zsolt Cselényi,Zsolt Cselényi,Peter Johnström,Peter Johnström,Magnus Schou,Magnus Schou,Ana Vazquez-Romero,Mohammad Mahdi Moein,Christer Halldin,Andrew P. Brown,Karthick Vishwanathan,Lars Farde,Lars Farde +16 more
TL;DR: This study in healthy volunteers shows that 11C-osimertinib penetrates the intact blood–brain barrier and illustrates the role of molecular imaging in facilitating the development of novel drugs for the treatment of malignancies affecting the brain.